Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.
The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.
advertisement
Here are three CRISPR developments we’re watching in 2024:
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
U.K. not yet recommending Vertex's CRISPR therapy for sickle cell
Next article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Moonlake's readout produced a cash windfall. Risks remain
